• Stream Info. Go to Chat & Listen to hear it!

    Currently Playing: Loading ...
    Station time:
  • iTunes TuneIn

STATINS – Serious Research Findings

dr-jim-roach

Sept. 18, 2016
Potential side effects of statin cholesterol medicine:
75% (128 patients) had cognitive side effects; 90% reported improvement with discontinuation (which means 10% had persisting cognitive impairment-JR). Pharmacotherapy July 2009
Promote aging – they prevented stem cells from performing their main functions, to reproduce and replicate other cells in the body to carry out repairs. Am J Physiology ‘15
Increased intra-cerebral hemorrhage – happened to one of my prominent patients
Increased diabetes risk in males – in a 2015 ten year VA study, statins increased diabetes mellitus type 2 87% and markedly increased the incidence of obesity
Promote arteriosclerosis (calcification of arteries) by lowering vitamin K
Induced deficiencies: CoQ10, vitamin B3, D, E, K, magnesium, selenium, copper, zinc, carnitine, creatine & glutathione
CoQ10 deficiency present in ‘Multiple Systems Atrophy’ affecting moving and involuntary bodily functions
Reduces glutathione – the main detoxifying nutrient substrate
Raise homocysteine, a marker for higher disease risk across the board through impaired detoxification
Lowers creatine, reducing muscle, vitality, brain function, and straining methylation (think ‘MTHFR’) which impairs detoxification, DNA repair, and many other key functions
Inhibit the immune system by reducing lymphocytes and anti-viral defense
Transient global amnesia can occur
Personality changes can occur
The relative risk of acute memory loss in the first 30 days of statin use was 4.4-fold that of those not on cholesterol medicine JAMA Internal Medicine 6/2015
Associated with a 16-fold increase in polyneuropathy, and 26-fold increased risk if on for 2 years. Neurology, 2002
Increased pneumonia risk 150%
Lowers hormones including testosterone (20% in my male patients)
Clinically in our office is a leading cause of Alzheimer’s dementia
Impairs thinking
Conflicting research on depression and anxiety
Hostility and aggression – 2 of 6 studies showed increased risk
Paranoia
Parkinsoin’s disease, ALS (amyotrophic lateral sclerosis)
Immune suppression with increased risk of infection
Associated with a 52% increased prevalence and extend of coronary artery plaques containing calcium. Atherosclerosis. 2012 Aug 24. Epub 2012 Aug 24. PMID: 22981406
Associated with increased coronary artery and aortic calcification in diabetics and
Omega-3 fatty acids (e.g. fish oil) benefits may be wiped out by statins.

A new study found treatment with statin cholesterol-lowering drugs caused a clinically silent but still definite damage to peripheral nerves when taken for longer than 2 years. At least 88 other studies further link statin drugs to neurotoxicity (nerve damage), including 12 studies on statin-induced peripheral neuropathy One study published in the journal Pharmacology in 2009, found statin-induced cognitive impairment to be a common occurrence, with 90% reporting improvement after drug discontinuation. There are, in fact, at least 12 studies linking memory problems with statin drug use in the biomedical literature, indicating just how widespread and serious a side effect statin-induced neurological damage really is.  Statin-associated adverse cognitive effects have been reported with 90% resolving after drug discontinuation. – GreenMedInfo Summary
Statin-associated adverse cognitive effects: survey results from 171 patients Pharmacotherapy. 2009 Jul ;29(7):800-11. PMID: 19558254 Department of Medicine, University of California-San Diego, La Jolla, California 92093-0995 RESULTS: 128 patients (75%) experienced cognitive ADRs determined to be probably or definitely related to statin therapy. Of 143 patients (84%) who reported stopping statin therapy, 128 (90%) reported improvement in cognitive problems, sometimes within days of statin discontinuation (median time to first-noted recovery 2.5 wks). Of interest, in some patients, a diagnosis of dementia or Alzheimer’s disease reportedly was reversed. Nineteen patients whose symptoms improved or resolved after they discontinued statin therapy and who underwent rechallenge with a statin exhibited cognitive problems again (multiple times in some). Within this vulnerable group, a powerful relationship was observed between potency of the statin and fraction of trials with that agent resulting in cognitive ADRs (p<0.00001). Quality of life was significantly adversely affected for each of the seven assessed domains (all p<0.00000001).CONCLUSION: Findings from the survey suggest that cognitive problems associated with statin therapy have variable onset and recovery courses, a clear relation to statin potency, and significant negative impact on quality-of-life. Administration of a patient-targeted questionnaire is a feasible approach that provides a useful complement to other ADR surveillance approaches. Pharmacotherapy.2009 July